Abstract:AI governance frameworks increasingly emphasize fairness, transparency, accountability, and lifecycle risk management in high-stakes domains. However, many current approaches remain observational, relying on static metric reporting, post-hoc auditing, and monitoring dashboards without directly governing deployment readiness, remediation progression, escalation states, or assurance-driven deployment control. This paper introduces Operational AI Deployment Assurance (OADA), a governance framework for translating fairness disagreement, subgroup instability, threshold sensitivity, remediation outcomes, and operational uncertainty into deployment-oriented assurance decisions. Building on prior work on the Fairness Disagreement Index (FDI) and FairRisk-FDI, OADA reframes governance uncertainty as an operational concern within AI deployment pipelines rather than a byproduct of metric disagreement. The framework introduces Deployment Assurance Scores, Deployment Readiness Classifications, Threshold Stability Zones, Governance Escalation States, and remediation-aware assurance progression. These constructs support lifecycle-oriented governance decisions across high-stakes settings by connecting evaluation outputs to deployment-state interpretation, reassessment, escalation, and operational control. Through deployment-oriented evaluation across facial recognition systems, with discussion extended to healthcare AI as a representative high-stakes domain, the paper demonstrates how systems may appear acceptable under isolated fairness or performance metrics while still exhibiting instability that affects deployment readiness. The proposed framework positions operational deployment assurance as a governance layer between evaluation and real-world AI deployment.
Abstract:The evaluation of fairness in machine learning systems has become a central concern in high-stakes applications, including biometric recognition, healthcare decision-making, and automated risk assessment. Existing approaches typically rely on a small number of fairness metrics to assess model behaviour across group partitions, implicitly assuming that these metrics provide consistent and reliable conclusions. However, different fairness metrics capture distinct statistical properties of model performance and may therefore produce conflicting assessments when applied to the same system. In this work, we investigate the consistency of fairness evaluation by conducting a systematic multi-metric analysis of demographic bias in machine learning models. Using face recognition as a controlled experimental setting, we evaluate model performance across multiple group partitions under a range of commonly used fairness metrics, including error-rate disparities and performance-based measures. Our results demonstrate that fairness assessments can vary significantly depending on the choice of metrics, leading to contradictory conclusions regarding model bias. To quantify this phenomenon, we introduce the Fairness Disagreement Index (FDI), a measure designed to capture the degree of inconsistency across fairness metrics. We further show that disagreement remains high across thresholds and model configurations. These findings highlight a critical limitation in current fairness evaluation practices and suggest that single-metric reporting is insufficient for reliable bias assessment.
Abstract:Artificial intelligence (AI) systems are increasingly integrated into healthcare and pharmacy workflows, supporting tasks such as medication recommendations, dosage determination, and drug interaction detection. While these systems often demonstrate strong performance under standard evaluation metrics, their reliability in real-world decision-making remains insufficiently understood. In high-risk domains such as medication management, even a single incorrect recommendation can result in severe patient harm. This paper examines the reliability of AI-assisted medication systems by focusing on system failures and their potential clinical consequences. Rather than evaluating performance solely through aggregate metrics, this work shifts attention towards how errors occur and what happens when AI systems produce incorrect outputs. Through a series of controlled, simulated scenarios involving drug interactions and dosage decisions, we analyse different types of system failures, including missed interactions, incorrect risk flagging, and inappropriate dosage recommendations. The findings highlight that AI errors in medication-related contexts can lead to adverse drug reactions, ineffective treatment, or delayed care, particularly when systems are used without sufficient human oversight. Furthermore, the paper discusses the risks of over-reliance on AI recommendations and the challenges posed by limited transparency in decision-making processes. This work contributes a reliability-focused perspective on AI evaluation in healthcare, emphasising the importance of understanding failure behavior and real-world impact. It highlights the need to complement traditional performance metrics with risk-aware evaluation approaches, particularly in safety-critical domains such as pharmacy practice.
Abstract:Artificial intelligence (AI) systems are increasingly integrated into healthcare and pharmacy workflows, supporting tasks such as medication recommendations, dosage determination, and drug interaction detection. While these systems often demonstrate strong performance under standard evaluation metrics, their reliability in real-world decision-making remains insufficiently understood. In high-risk domains such as medication management, even a single incorrect recommendation can result in severe patient harm. This paper examines the reliability of AI-assisted medication systems by focusing on system failures and their potential clinical consequences. Rather than evaluating performance solely through aggregate metrics, this work shifts attention towards how errors occur and what happens when AI systems produce incorrect outputs. Through a series of controlled, simulated scenarios involving drug interactions and dosage decisions, we analyse different types of system failures, including missed interactions, incorrect risk flagging, and inappropriate dosage recommendations. The findings highlight that AI errors in medication-related contexts can lead to adverse drug reactions, ineffective treatment, or delayed care, particularly when systems are used without sufficient human oversight. Furthermore, the paper discusses the risks of over-reliance on AI recommendations and the challenges posed by limited transparency in decision-making processes. This work contributes a reliability-focused perspective on AI evaluation in healthcare, emphasising the importance of understanding failure behavior and real-world impact. It highlights the need to complement traditional performance metrics with risk-aware evaluation approaches, particularly in safety-critical domains such as pharmacy practice.
Abstract:Facial recognition systems are increasingly deployed in law enforcement and security contexts, where algorithmic decisions can carry significant societal consequences. Despite high reported accuracy, growing evidence demonstrates that such systems often exhibit uneven performance across demographic groups, leading to disproportionate error rates and potential harm. This paper argues that aggregate accuracy is an insufficient metric for evaluating the fairness and reliability of facial recognition systems in high-stakes environments. Through analysis of subgroup-level error distribution, including false positive rate (FPR) and false negative rate (FNR), the paper demonstrates how aggregate performance metrics can obscure critical disparities across demographic groups. Empirical observations show that systems with similar overall accuracy can exhibit substantially different fairness profiles, with subgroup error rates varying significantly despite a single aggregate metric. The paper further examines the operational risks associated with accuracy-centric evaluation practices in law enforcement applications, where misclassification may result in wrongful suspicion or missed identification. It highlights the importance of fairness-aware evaluation approaches and model-agnostic auditing strategies that enable post-deployment assessment of real-world systems. The findings emphasise the need to move beyond accuracy as a primary metric and adopt more comprehensive evaluation frameworks for responsible AI deployment.